Your browser doesn't support javascript.
Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.
Patell, Rushad; Chiasakul, Thita; Bauer, Ethan; Zwicker, Jeffrey I.
  • Patell R; Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
  • Chiasakul T; Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
  • Bauer E; Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Zwicker JI; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Thromb Haemost ; 121(1): 76-85, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-1066012
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of escalated-dose pharmacologic thromboprophylaxis are not established.

OBJECTIVES:

To determine the pooled incidence of thrombosis/bleeding in hospitalized patients with COVID-19 for standard-dose, intermediate-dose, therapeutic anticoagulation, and no pharmacologic thromboprophylaxis.

METHODS:

MEDLINE, EMBASE, and Cochrane CENTRAL were searched up to August 29, 2020 for studies reporting pharmacologic thromboprophylaxis and thrombosis or bleeding. Pooled event rates were calculated using a random-effects model.

RESULTS:

Thirty-five observational studies were included. The pooled incidence rates of total venous thromboembolism (N = 4,685) were no prophylaxis 41.9% (95% confidence interval [CI] 28.1-57.2, I 2 = 76%), standard-dose prophylaxis 19.8% (95% CI 13.2-28.6, I 2 = 95%), intermediate-dose prophylaxis 11.9% (95% CI 4.3-28.6, I 2 = 91%), and therapeutic-dose anticoagulants 10.5% (95% CI 4.2-23.8, I 2 = 82%, p = 0.003). The pooled incidence rates of arterial thrombosis (N = 1,464) were no prophylaxis 11.3% (95% CI 5.2-23.0, I 2 = 0%), standard-dose prophylaxis 2.5% (95% CI 1.4-4.3, I 2 = 45%), intermediate-dose prophylaxis 2.1% (95% CI 0.5-7.7, I 2 = 45%), and therapeutic-dose anticoagulants 1.3% (95% CI 0.2-8.8, I 2 = 0, p = 0.009). The pooled bleeding event rates (N = 6,393) were nonsignificantly higher in therapeutic-dose anticoagulants compared with standard-dose prophylaxis, (6.3 vs. 1.7%, p = 0.083).

CONCLUSION:

Thrombosis rates were lower in hospitalized COVID-19 patients who received pharmacologic thromboprophylaxis. Thrombosis and bleeding rates for patients receiving intermediate-dose thromboprophylaxis or therapeutic anticoagulation were similar to those who received standard-dose pharmacologic thromboprophylaxis.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Coagulation / Venous Thromboembolism / Fibrinolytic Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Hospitalization Type of study: Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Thromb Haemost Year: 2021 Document Type: Article Affiliation country: S-0040-1721664

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Coagulation / Venous Thromboembolism / Fibrinolytic Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Hospitalization Type of study: Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Thromb Haemost Year: 2021 Document Type: Article Affiliation country: S-0040-1721664